Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Capsicum Oleoresin→

Capsicum Oleoresin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
8023-77-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Capsaicinoid-containing botanical extracttopical counterirritant and analgesic ingredient
Mechanism of action
Capsaicinoids activate TRPV1 on peripheral sensory neurons and, with repeated exposure, produce functional desensitisation and reduced nociceptive signalling. Extract composition and capsaicin concentration vary by botanical source and formulation.
Indications / reported uses
  • Topical symptomatic relief of minor muscle and joint pain in external analgesic products
  • Where standardised capsaicinoid products are authorised, use for selected localised neuropathic pain; do not assume all oleoresin formulations have equivalent potency or indications

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · PubMed — Capsicum oleoresin topical analgesia · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Capsaicinoid-containing botanical extract; topical counterirritant and analgesic ingredient

Mechanism of action

Capsaicinoids activate TRPV1 on peripheral sensory neurons and, with repeated exposure, produce functional desensitisation and reduced nociceptive signalling. Extract composition and capsaicin concentration vary by botanical source and formulation.

General use cases

  • Topical symptomatic relief of minor muscle and joint pain in external analgesic products
  • Where standardised capsaicinoid products are authorised, use for selected localised neuropathic pain; do not assume all oleoresin formulations have equivalent potency or indications

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Capsicum Oleoresin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Capsicum Oleoresin Permitted Daily Exposure (PDE) report (the Capsicum Oleoresin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Capsicum Oleoresin Occupational Exposure Limit (OEL) report (the Capsicum Oleoresin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.